Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01540071 · ClinicalTrials.gov registry record · Phase 2

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

A Phase 2 study of Castration-resistant Prostate Cancer, sponsored by Io Therapeutics.

Completed
Registry status
Phase 2
Development phase
38
Enrollment target
1
Study location

NCT01540071: Completed Phase 2 study of Castration-resistant Prostate Cancer, sponsored by Io Therapeutics.

NCT01540071 is a Phase 2 study of Castration-resistant Prostate Cancer that has completed, run by Io Therapeutics. The registered enrollment target is 38 participants, below the 215-participant average among 15 other Castration-resistant Prostate Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01540071, a Phase 2 study of Castration-resistant Prostate Cancer, has completed, sponsored by Io Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.

Primary Outcome

Clinical benefit will be defined as either non-progression at 8 weeks or radiologic and/or PSA response at any time point with no dose limiting toxicity (DLT) or other toxicity requiring termination of treatment.

Conditions Studied

Castration-resistant Prostate Cancer

Interventions

  • DRUG NRX 194204

Study Locations (1)

California

  • Lalita Pandit, MD - Fountain Valley

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2011-08
Est. Completion 2015-12
Phase Phase 2
Io Therapeutics

3 total trials

What the finished NCT01540071 record still lists

NCT01540071 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 215-participant average among 15 other Castration-resistant Prostate Cancer trials with a reported enrollment target (82% lower).

The record links to 1 condition, with Castration-resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which NRX 194204 is the first listed.

NCT01540071 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01540071 about?

NCT01540071 is a clinical study titled "Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer". This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.

What is the current status of trial NCT01540071?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2011-08. Estimated completion is 2015-12.

What conditions does trial NCT01540071 study?

This clinical trial studies the following conditions: Castration-resistant Prostate Cancer.

What interventions are being tested in trial NCT01540071?

The interventions under investigation include: NRX 194204 (DRUG).

Who is sponsoring clinical trial NCT01540071?

This trial is sponsored by Io Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01540071 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Castration-resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01540071's enrollment target sits among peer trials

38 12th of 15 higher than 4 of 15 other Castration-resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Castration-resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01540071, the US trial registry maintained by the National Library of Medicine. NCT01540071 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.